Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | PNMT | P11086 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29724224 | 1.00 | HTR2A (0.64) | HTR2AHTR2CHTR2BPNMTKDM1A | |
| Hydrochloric Acid SCHEMBL27261560 | 0.97 | HTR2A (0.61) | HTR2AHTR2CHTR2BPNMTKDM1A | |
| SCHEMBL5221227 | 0.95 | HTR2A (0.64) | HTR2AHTR2CHTR2BPNMTKDM1A | |
| SCHEMBL30218134 | 0.95 | HTR2A (0.64) | HTR2AHTR2CHTR2BPNMTKDM1A | |
| SCHEMBL15962624 | 0.89 | — | — | |
| Ammonia Solution, Strong SCHEMBL10465265 | 0.86 | HTR2A (0.67) | HTR2AHTR2CHTR2BPNMTKDM1A | |
| SCHEMBL23188936 | 0.84 | HTR2A (0.53) | HTR2AHTR2CHTR2BPNMTKDM1A | |
| SCHEMBL16559360 | 0.79 | HTR2A (0.58) | HTR2AHTR2CHTR2BPNMTKDM1A | |
| SCHEMBL2881688 | 0.78 | HTR2C (1.00) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL29676733 | 0.78 | HTR2C (1.00) | HTR2AHTR2CHTR2BPNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423431-B1 | CARBAMATE DERIVATIVE COMPOUNDS AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| CN-109923113-B | Isoxazolyl ether derivatives as GABA A alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230303513-A1 | OXOPYRROLIDINE UREA FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-28 | — | — | US | disclosed |
| US-20220332708-A1 | SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS | CYTOKINETICS INC (US) | 2022-10-20 | — | — | US | disclosed |
| WO-2022127827-A1 | KRASG12C PROTEIN MUTATION INHIBITOR AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 上海维申医药有限公司 | 2022-06-23 | — | — | WO | disclosed |
| US-11318133-B2 | Modulators of integrated stress response pathway | Praxis Biotech LLC (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2022035923-A1 | OXOPYRROLIDINE UREA FPR2 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20210317102-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ALTOS LABS, INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2020252205-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200390759-A1 | MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2020-12-17 | — | — | US | disclosed |
| EP-0657427-B1 | Tricyclic indole-2-carboxylic acid derivatives being selective antagonists of the NMDA receptor | SUMITOMO PHARMA (JP) | 2002-06-19 | — | — | EP | disclosed |
| EP-0756594-B1 | PREPARATION OF ARTHROPODICIDAL OXADIAZINES | DU PONT (US) | 2002-03-13 | — | — | EP | disclosed |
| US-6232489-B1 | RACEMIC MIXTURES, ENANTIOMORPHS | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-05-15 | — | — | US | disclosed |
| CN-1061034-C | Tricyclic indole-2-carboxylic acid derivatives | SUMITOMO PHARMA (JP) | 2001-01-24 | — | — | CN | disclosed |
| EP-1048647-A1 | N-Chlorocarbonyl-carbamate derivative and its use in the preparation of arthropodicidal oxadiazines | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6080856-A | Preparation of arthropodicidal oxadiazines | E. I. DU PONT NEMOURS AND COMPANY (US) | 2000-06-27 | — | — | US | disclosed |
| US-6018071-A | Preparation of arthropodicidal ozadiazines | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-01-25 | — | — | US | disclosed |
| US-5496843-A | Tricyclic indole-2-carboxylic acid derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-03-05 | — | — | US | disclosed |
| CN-1107838-A | Tricyclic indole-2-carboxylic acid derivatives | SUMITOMO PHARMA (JP) | 1995-09-06 | — | — | CN | disclosed |
| EP-0657427-A1 | Tricyclic indole-2-carboxylic acid derivatives being selective antagonists of the NMDA receptor | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1995-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303513-A1 | OXOPYRROLIDINE UREA FPR2 AGONISTS | FPR1, FPR2, FPR3 | HTR2A 985/4885HTR2C 1298/4885HTR2B 1341/4885 |
| US-20210317102-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | HTR2A 1310/4885HTR2C 1125/4885HTR2B 1489/4885 |
| US-20220332708-A1 | SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS | TNNT2, TNNI3, MYLK2 | HTR2A 2280/4885HTR2C 3812/4885HTR2B 3319/4885 |
| US-20200390759-A1 | MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, ATF1, DDIT3 | HTR2A 717/4885HTR2C 774/4885HTR2B 1407/4885 |
| US-11318133-B2 | Modulators of integrated stress response pathway | ATF4, ATF1, DDIT3 | HTR2A 717/4885HTR2C 774/4885HTR2B 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.